Menin Inhibitors at ASH 2026: Combinations, MRD-Directed Use and Resistance

Menin inhibition appears in clinical and preclinical oral abstracts.

• Abstract 66 (Oral, 10:45–11:00 AM): Ziftomenib + gilteritinib in relapsed/refractory NPM1 and FLT3 co-mutated AML, KOMET-008 Phase 1 (Goldberg; NCT06001788).
• Abstract 388 (Oral, 4:45–5:00 PM): Revumenib as pre-emptive therapy for MRD in NPM1-mutated or KMT2A-rearranged AML, ALLG AMLM26 INTERCEPT platform trial (Loo).
• Abstract 227 (Oral): ASXL1 mutations and menin inhibition, with XPO1 blockade (Mill).
• Abstract 363 (Oral): “Drug-tolerant persister cells retain disease-initiating potential under menin inhibition” (Klaus).
• Abstract 453 (Oral): “Overcoming clinically relevant menin resistance mutations with CHM-056…” (Ofir-Rosenfeld).

The titles span combination approaches, MRD-triggered treatment and resistance biology, themes AML trial teams will want to follow.